Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges

IF 12.1 1区医学 Q1 ONCOLOGY Seminars in cancer biology Pub Date : 2023-11-04 DOI:10.1016/j.semcancer.2023.11.002

Mundla Srilatha , Ramarao Malla , Megha Priya Adem , Jeremy B. Foote , Ganji Purnachandra Nagaraju

{"title":"Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges","authors":"Mundla Srilatha , Ramarao Malla , Megha Priya Adem , Jeremy B. Foote , Ganji Purnachandra Nagaraju","doi":"10.1016/j.semcancer.2023.11.002","DOIUrl":null,"url":null,"abstract":"<div><p>Obesity is a prominent health issue worldwide and directly impacts pancreatic health, with obese individuals exhibiting a significant risk for increasing pancreatic ductal adenocarcinoma (PDAC). Several factors potentially explain the increased risk for the development of PDAC, including obesity-induced chronic inflammation within and outside of the pancreas, development of insulin resistance and metabolic dysfunction, promotion of immune suppression within the pancreas during inflammation, pre- and malignant stages, variations in hormones levels (adiponectin, ghrelin, and leptin) produced from the adipose tissue, and acquisition of somatic mutations in tumor once- and suppressor proteins critical for pancreatic tumorigenesis. In this manuscript, we will explore the broad impact of these obesity-induced risk factors on the development and progression of PDAC, focusing on changes within the tumor microenvironment (TME) as they pertain to prevention, current therapeutic strategies, and future directions for targeting obesity management as they relate to the prevention of pancreatic tumorigenesis.</p></div>","PeriodicalId":21594,"journal":{"name":"Seminars in cancer biology","volume":null,"pages":null},"PeriodicalIF":12.1000,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1044579X23001359/pdfft?md5=74a4a7208e69d203a204322e1c0fe9fd&pid=1-s2.0-S1044579X23001359-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in cancer biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1044579X23001359","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Obesity is a prominent health issue worldwide and directly impacts pancreatic health, with obese individuals exhibiting a significant risk for increasing pancreatic ductal adenocarcinoma (PDAC). Several factors potentially explain the increased risk for the development of PDAC, including obesity-induced chronic inflammation within and outside of the pancreas, development of insulin resistance and metabolic dysfunction, promotion of immune suppression within the pancreas during inflammation, pre- and malignant stages, variations in hormones levels (adiponectin, ghrelin, and leptin) produced from the adipose tissue, and acquisition of somatic mutations in tumor once- and suppressor proteins critical for pancreatic tumorigenesis. In this manuscript, we will explore the broad impact of these obesity-induced risk factors on the development and progression of PDAC, focusing on changes within the tumor microenvironment (TME) as they pertain to prevention, current therapeutic strategies, and future directions for targeting obesity management as they relate to the prevention of pancreatic tumorigenesis.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肥胖相关的胰腺导管腺癌：治疗挑战。

肥胖是世界范围内一个突出的健康问题，直接影响胰腺健康，肥胖者表现出增加胰腺导管腺癌（PDAC）的显著风险。有几个因素可能解释PDAC发展风险的增加，包括肥胖诱导的胰腺内外慢性炎症、胰岛素抵抗和代谢功能障碍的发展、炎症期间胰腺内免疫抑制的促进、前和恶性阶段，脂肪组织产生的激素水平（脂联素、胃饥饿素和瘦素）的变化，以及对胰腺肿瘤发生至关重要的肿瘤一次和抑制蛋白的体细胞突变。在这篇文章中，我们将探讨这些肥胖诱导的风险因素对PDAC的发展和进展的广泛影响，重点关注肿瘤微环境（TME）中与预防有关的变化，当前的治疗策略，以及针对肥胖管理的未来方向，因为它们与预防胰腺肿瘤发生有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Seminars in cancer biology 医学-肿瘤学

CiteScore

26.80

自引率

4.10%

发文量

347

审稿时长

15.1 weeks

期刊介绍： Seminars in Cancer Biology (YSCBI) is a specialized review journal that focuses on the field of molecular oncology. Its primary objective is to keep scientists up-to-date with the latest developments in this field. The journal adopts a thematic approach, dedicating each issue to an important topic of interest to cancer biologists. These topics cover a range of research areas, including the underlying genetic and molecular causes of cellular transformation and cancer, as well as the molecular basis of potential therapies. To ensure the highest quality and expertise, every issue is supervised by a guest editor or editors who are internationally recognized experts in the respective field. Each issue features approximately eight to twelve authoritative invited reviews that cover various aspects of the chosen subject area. The ultimate goal of each issue of YSCBI is to offer a cohesive, easily comprehensible, and engaging overview of the selected topic. The journal strives to provide scientists with a coordinated and lively examination of the latest developments in the field of molecular oncology.

期刊最新文献

Extracellular vesicles and biomarker discovery cGAS/STING signalling pathway in senescence and oncogenesis Combined targeting of senescent cells and senescent macrophages: A new idea for integrated treatment of lung cancer Editorial Board Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]